Immunoglobulins (Ig), commonly derived from bovine colostrum, are antibody proteins that support immune function and intestinal health. They work by binding to pathogens and toxins in the gastrointestinal tract, preventing their adherence to mucosal surfaces and supporting barrier integrity. Oral immunoglobulin supplementation is primarily used for immune support, gut healing, and reducing upper respiratory tract infections.

Overview

Immunoglobulins (Ig), also known as antibodies, are large Y-shaped glycoproteins produced by plasma cells (differentiated B lymphocytes) that serve as the cornerstone of adaptive humoral immunity. The five major classes — IgG, IgA, IgM, IgD, and IgE — each play distinct roles in immune defense, from neutralizing pathogens and toxins (IgG) to protecting mucosal surfaces (IgA) and mediating allergic responses (IgE). Intravenous immunoglobulin (IVIG), derived from pooled human plasma, is an established FDA-approved therapy for primary immunodeficiency disorders, idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy, among other conditions.

Beyond intravenous administration, oral immunoglobulin supplementation has gained attention for gut health applications. Serum-derived bovine immunoglobulin/protein isolate (SBI), marketed as EnteraGam, contains high concentrations of IgG antibodies that bind microbial antigens, endotoxins, and inflammatory mediators in the gut lumen. Clinical studies in patients with irritable bowel syndrome with diarrhea (IBS-D) and HIV-associated enteropathy have demonstrated improvements in stool consistency, abdominal pain, and markers of intestinal permeability. Colostrum-derived immunoglobulins (found in colostrum supplements) similarly provide IgG, IgA, and IgM that support mucosal immunity and gut barrier function, with particular relevance for athletes experiencing exercise-induced immunosuppression.

The mechanism by which oral immunoglobulins support gut health involves direct binding and neutralization of luminal antigens, reduction of immune activation at the intestinal epithelium, and support of tight junction integrity. This "immune exclusion" function reduces the translocation of bacterial endotoxins and inflammatory triggers across the gut barrier, complementing the actions of l-glutamine, zinc-l-carnosine, and lactoferrin in protocols targeting intestinal permeability (leaky gut). Typical SBI supplementation provides 5–10 grams daily of immunoglobulin-rich protein. Oral immunoglobulins are generally well-tolerated and represent a targeted approach to immune support that works at the critical interface between the gut microbiome and systemic immune function.

Mechanism of Action

Immunoglobulins (antibodies) are glycoprotein molecules produced by plasma cells (differentiated B lymphocytes) that form the humoral arm of the adaptive immune system. They exist in five isotypes—IgG, IgA, IgM, IgE, and IgD—each with distinct structural features and functional roles. All immunoglobulins share the ability to recognize and bind specific antigens through their variable (Fab) regions, while their constant (Fc) regions mediate effector functions by interacting with immune cells and complement proteins.

IgG is the most abundant serum immunoglobulin and mediates neutralization, opsonization, complement activation via the classical pathway, and ADCC through Fc receptor engagement on NK cells. IgM, a pentameric antibody, is the first responder in primary immune responses and is exceptionally efficient at complement activation and pathogen agglutination. IgA, predominantly found as secretory IgA at mucosal surfaces, prevents pathogen adhesion and penetration in the respiratory, gastrointestinal, and urogenital tracts. IgE binds to high-affinity FceRI receptors on mast cells and basophils; allergen cross-linking triggers degranulation and release of histamine and other mediators, driving allergic responses and anti-parasitic defense.

Therapeutically, immunoglobulins are used as intravenous immunoglobulin (IVIG) for immunodeficiency disorders, autoimmune conditions, and inflammatory diseases. IVIG works through multiple mechanisms including Fc receptor blockade, anti-idiotypic antibody interactions, complement scavenging, and modulation of cytokine networks. Specific monoclonal antibodies are also engineered for targeted therapy in oncology, autoimmune disease, and infectious disease.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Immunoglobulins (IVIg / SCIg)

Common Side Effects

• Infusion-related reactions (most common, up to 40% of first infusions): headache, chills, fever, myalgia, nausea, and fatigue
• Back pain and arthralgia during or shortly after infusion
• Injection site reactions with subcutaneous administration: swelling, redness, and localized pain
• Mild hypertension or hypotension during IV infusion
• Fatigue lasting 24–72 hours post-infusion ("IVIg hangover")

Serious Adverse Effects

• Thromboembolic events (BOXED WARNING): deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, particularly at high doses (≥1 g/kg) and rapid infusion rates
• Renal dysfunction and acute renal failure: especially with sucrose-containing formulations; risk increased in patients >65, diabetic, or with pre-existing renal impairment
• Aseptic meningitis syndrome: severe headache, nuchal rigidity, photophobia, and fever occurring 24–48 hours post-infusion; incidence ~1–11%
• Hemolytic anemia: IVIg contains anti-A and anti-B isohemagglutinins; non-O blood type patients at higher risk (positive DAT in up to 30%)
• Anaphylaxis: rare but potentially fatal, particularly in IgA-deficient patients with anti-IgA antibodies
• Transfusion-related acute lung injury (TRALI): rare but life-threatening pulmonary edema

Contraindications

• Selective IgA deficiency with documented anti-IgA antibodies (anaphylaxis risk)
• History of anaphylactic reaction to immunoglobulin products
• Acute renal failure or severe renal impairment (especially for sucrose-containing products)
• Uncontrolled congestive heart failure (volume overload risk)
• Known hyperprocoagulable states (without concurrent anticoagulation)

Drug Interactions

• Live vaccines (MMR, varicella, yellow fever): immunoglobulins neutralize live vaccine antigens; wait 3–11 months after IVIg before administering live vaccines
• Anticoagulants: thromboembolic risk may paradoxically co-exist with IVIg therapy; careful anticoagulation management required
• Nephrotoxic drugs (aminoglycosides, NSAIDs, contrast dye): additive renal injury risk
• Loop diuretics: may be needed to manage volume overload but can worsen renal function
• Serological testing: IVIg contains diverse antibodies that may cause false-positive results for infections (CMV, hepatitis, parvovirus) for weeks post-infusion

Population-Specific Considerations

• Pregnancy: Category C; used in pregnancy for specific indications (recurrent pregnancy loss, neonatal alloimmune thrombocytopenia); benefits may outweigh risks under specialist guidance
• Elderly (>65 years): highest risk for renal failure and thromboembolic events; use lowest effective dose, slowest tolerated infusion rate, and ensure adequate hydration
• Pediatric patients: generally well tolerated; weight-based dosing applies; monitor for hemolysis in neonates
• Cardiac patients: volume overload risk; pre-infusion assessment and slower infusion rates essential
• Diabetic patients: sucrose-stabilized products contraindicated; use alternative formulations (proline, glycine, or L-isoleucine stabilized)

Pharmacokinetic Profile